These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33910464)

  • 1. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
    Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
    Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.
    Laliberté F; Ashton V; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Berger JS
    J Comp Eff Res; 2021 Nov; 10(16):1235-1250. PubMed ID: 34378989
    [No Abstract]   [Full Text] [Related]  

  • 6. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    Curr Med Res Opin; 2021 Jun; 37(6):881-890. PubMed ID: 33733969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
    Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
    Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
    Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):203-212. PubMed ID: 30251553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
    Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
    Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin.
    Milentijevic D; Lin JH; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts M
    J Med Econ; 2021; 24(1):212-217. PubMed ID: 33499689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation.
    Francis K; Yu C; Alvrtsyan H; Sander S; Ghosh S; Rao Y; Sanchez H; Matchar D
    Curr Med Res Opin; 2015 Dec; 31(12):2189-95. PubMed ID: 26359333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
    Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
    Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
    Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
    Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.